Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OT-In honor of our heros-
OT: Freedom Isn't Free
I watched the flag pass by one day.
It fluttered in the breeze
A young soldier saluted it, and then
He stood at ease.
I looked at him in uniform
So young, so tall, so proud
With hair cut square and eyes alert
He'd stand out in any crowd.
I thought how many men like him
Had fallen through the years.
How many died on foreign soil?
How many mothers' tears?
How many Pilots' planes shot down?
How many foxholes were soldiers' graves?
No, Freedom isn't free
I heard the sound of taps one night,
When everything was still.
I listened to the bugler play
And felt a sudden chill.
I wondered just how many times
That taps had meant "Amen"
When a flag had draped a coffin
of a brother or a friend.
I thought of all the children,
Of the mothers and the wives,
Of fathers, sons and husbands
With interrupted lives.
I thought about a graveyard at the
bottom of the sea
Of unmarked graves in Arlington.....
No -- Freedom isn't free!!
Cadet Major Kelly Strong
Air Force Junior ROTC
In honor of our heros-
I watched the flag pass by one day.
It fluttered in the breeze
A young soldier saluted it, and then
He stood at ease.
I looked at him in uniform
So young, so tall, so proud
With hair cut square and eyes alert
He'd stand out in any crowd.
I thought how many men like him
Had fallen through the years.
How many died on foreign soil?
How many mothers' tears?
How many Pilots' planes shot down?
How many foxholes were soldiers' graves?
No, Freedom isn't free
I heard the sound of taps one night,
When everything was still.
I listened to the bugler play
And felt a sudden chill.
I wondered just how many times
That taps had meant "Amen"
When a flag had draped a coffin
of a brother or a friend.
I thought of all the children,
Of the mothers and the wives,
Of fathers, sons and husbands
With interrupted lives.
I thought about a graveyard at the
bottom of the sea
Of unmarked graves in Arlington.....
No -- Freedom isn't free!!
Cadet Major Kelly Strong
Air Force Junior ROTC
I think most everyone believed farkin Parkin at one time,including me, but after so many bald faced lies one soon learns.
I wonder if this poster ever "saw the light"? He is still pumping SLJB,lol.
*
Posted by: cm3i long termer
In reply to: None Date:7/18/2006 4:08:31 PM
Post #of 33292
Fellow NDOLites
I spoke to Mr. Perkin this morning. He said the following:
1) The symbol/name change was delayed due to some more info the SEC required. All has been sent again, and they anticipate the name change, symbol change, and OTCBB listing to all happen simultaneously, and shortly.
All is in the hands of the SEC at present.
2) The paperwork signing for the US PR firm is being signed today or tomorrow. The news would follow as soon as signings were completed. He would not disclose the firm name and number. He felt that the US shareholders would flood them with calls before the final signing.
3) The India Oil JV is A done deal. All signings and news should be out by weeks end. Next week at the latest.
I thanked him for the great job that he and the company are doing.
We just need to press through this low time, and we will reap the rewards. This is a buying season for those that still have gun powder.
Remember that legal crap always takes longer than they predict. We are still acouple months from the acquisition completions.
As Brent always says......"KEEP THE FAITH".
Words are powerful, so speak and think positvely about NDOL, and life in general.
Don't get to down. It will turn around, and IMO it will blast off like a rocket when all they are doing is completed.
God Bless you all
ADOV spam/scammers on a Sunday,lol.
THE INTERNET SECTOR IS HOT AGAIN...
Sumb0l: ADOV
Current: $0.52
3 Day Target price: $2.50
Recommendation: very aggresive buy!
500% profit potential short term..
Thanks Bio, I know nothing about the drug-just what was posted re FDA. Post did say FDA voted 31-4 in favor of efficacy.
Found this on another board. Any comments on what seems (on the surface) an advisory committee scam?
------
My latest disappointment is DNDN, Dendreon - producer of the drug Provenge for END STAGE PROSTATE CANCER, in which the patients are basically terminal. Had the FDA's Advisory Committee on record of voting 17-0 for safety; 31-4 for efficacy.
It was a slam dunk for most who owned shares.
The FDA then comes out with an "approvable" CR letter, saying they needed more information.
Prices plummet 17 to 7 before the market opening. The fix was in, the market traded close to 130 million shares that day, when the A/S was only 82 million and the shorts officially were noted at 42 million, naked shorting was rampant within the hedge fund bunch. They stood to lose one BILLION dollars had the drug been outright approved.
A couple of scientists on the advisory company who had COI (conflicts of interest) actually circulated PUBLICLY letters trying to make sure the drug was not approved. (One of those was a MD woman who was one of the 4 "no" votes and was noted as being ASLEEP during the presentation to the ADvisory Commitee).
Remember this is a drug that is totally safe -- and taken by men who are about to die. The politics of power, money and personal vendettas kicked in. The issue is that chemotherapy doctors and pharms making cash off of chemotherapeutic chemicals do NOT want immunotherapy to be the next standard of care for cancer patients - the paradigm shift that would have begun to happen with this drug.
The forces that be are now trying to take down the company using any method to do so.
Activists from all walks of life are responding, from cancer patients to oncologists to investors to try to influence the head of the FDA - Dr. Andrew C. von Eschenbach - to right this wrong. The kicker is that Von E himself is a prostate cancer survivor and sent STRONG signals prior to the CR letter that he was hell bent on changing the way the FDA viewed this science.
The FDA asked for more data because it turned its back on the fact the end point the company rested its studies on was PATIENT SURVIVAL - and supposedly missed the MATHEMATICAL STATISTICAL ENDPOINT NUMBERS by a couple hundredths of a percent. That the FDA would not approve in the face of the company displaying real life surviving patients because of a "need for more STATISTICAL information" while there basically is NO treatment for the disease astounded everyone::
See Provengenow for more information (this is an activists site, not a company sponsored one::
http://www.provengenow.org/
Along with a half dozen other deceiving pumpers and bashers!
Yep, sure is!
Well there must be dozens of "females" on this board as they go "on and on" with hundreds of redundant, piontless, misinformation and useless chatter.
Thanks to those who do post useful information.
Is the SEC a crooks best friend????
http://www.nypost.com/seven/05252007/business/report_rips_cox_business_paul_tharp.htm
Strongus-NWOG admitted that Parkin lied to us re the "buyout" and he sold into his pump,IMO. Do you think he will go to jail over this or do you think NWOG will attempt to recover some ill gotten funds from him?
Nevada- a scam haven for crooks, including email crooks!
http://www.lasvegassun.com/sunbin/stories/text/2007/apr/29/566674820.html
Crooks do not like for the truth to be in the public domain :)
Did Select American Transfer (SAT) have any connections to pinks listed on this board? Will any SAT honchos be going to jail?
http://osc.gov.on.ca/Enforcement/Proceedings/RAD/rad_20070518_select-american.pdf
The Wall Street Analyst Forum conference May 22nd - May 24th at the Princeton Club in New York City on West 43rd St. features presentations from companies in the Technology, BioTech, Security and Financial Services industries. (See list below of Scheduled Presenting companies). The forum also features chief investment strategist presentations by Sam Stovall of Standard & Poor's and Michael Metz of Oppenheimer & Co.
About GVI Security Solutions, Inc.
GVI Security Solutions Inc. is a leading provider of video surveillance security solutions to the homeland security, institutional and commercial market segments.
About The Wall Street Analyst Forum
Since 1988, The Wall Street Analyst Forum has been a sponsor of four annual analyst conferences for the CEO/CFO's of NYSE/NASDAQ/AMEX corporations in New York, Boston and London.
Scheduled companies Insert Therapeutics (NASDAQ: ARWR), MFIC Corp. (OTCBB: MFIC), Neural Stem, Inc. (OTCBB: NRLS), Cardium Therapeutics, Inc. (OTCBB: CDTP), AspenBio Pharma, Inc. (OTCBB: APNB) Innovive Pharmaceuticals (OTCBB: IVPH), Aradigm Corporation (OTCBB: ARDM), Avicena Group (OTCBB: AVGO), Heska Corporation (NASDAQ: HSKA), HealthSonix Inc. (Pink Sheet: HSXI), Capital Senior Living Corp. (NYSE: CSU), Sharps Compliance Corp. (OTCBB: SCOM), Castle Brands Inc. (AMEX: ROX), GVI Security Solutions, Inc. (OTCBB: GVSS), AeroMechanical Services Ltd. (TSX VENTURE: AMA.V), Optionable Inc. (OTCBB: OPBL), Bank of Internet USA (NASDAQ: BOFI) and Lithium Technology Corp (Pink sheets: LTHU).
From in-PharmaTechnologist.com:
MFIC to bring microfluidics to drug formulation
May 24, 2007
By Matt Wilkinson
Get the latest Market Reports on:
MFIC
MRT
microfluidics
crystallisation
drug formulation
Related News:
Prosonix wins award for SAX
New technologies, needs will spur transdermal/transmucosal delivery
MFIC's fortunes recover on the back of strong sales
Avantium pushes crystallisation services forward
Aptuit embarks on $100m spending spree
MFIC to boost nanomaterials development
MFIC is looking to introduce a new microfluidic system that could help pharmaceutical and biotechnology companies to manufacture difficult to formulate drugs.
The new device is a product of the US company's Microfluidics Reaction Technology (MRT) development program and works by creating nanosuspensions that can then be easily used in drug formulation.
The new technology was presented at the Nano Science and Technology Institute (NSTI) Nanotech conference 2007 in Santa Clara, California, US, earlier this week.
MFIC demonstrated the potential of the new technique for a series of drugs with masses ranging between 220 and 750 AMU (atomic mass units).
"The advent of MRT could potentially unlock uncounted drugs, vaccines and drug delivery systems that to date could not be formulated," said Bob Bruno, CEO of MFIC Corp.
Bruno anticipates introducing a range of equipment to enable the MRT process in the fourth quarter of the year, "providing our customers with an additional effective and efficient solution for the creation of promising, new therapeutics".
Conventional "top down" processes take a bulk product and reduce the size of the particles by processes such as wet-milling, homogenisation and micronisation.
These processes give inconsistent results that can be problematic for batch to batch consistency and when making drugs for inhalation.
The MRT uses a "bottom up" approach that pumps the drug containing solvent and anti-solvent at each other within a 'Microfluidizer' reaction chamber at velocities of up to 400m/s.
The reaction chamber provides precise control of the feed rate and mixing location to produce uniform, optimally-sized nanoparticles by solvent, anti-solvent and surfactant crystallisation techniques.
"Through the use of MRT, MFIC engineers were able to produce nanosuspensions for several drugs," said Dr. Thomai Panagiotou, vice president of R&D at MFIC.
"Importantly, MRT was demonstrated to be more effective in producing nanosuspensions than standard, particle size reducing methods."
good chart-thanks
CEL-SCI'S CEL-1000 Shown To Significantly Enhance Immune Response Against Avian Flu Antigen In Animals
Main Category: Bird Flu / Avian Flu News
Article Date: 24 May 2007 - 0:00 PDT
| email to a friend | printer friendly | view or write opinions | Article Also Appears In
Immune System / Vaccines
rate this article
CEL-SCI CORPORATION (Amex: CVM) announces that CEL-1000 increased the immune response against H5 avian influenza antigen in combination with MAS-1, a water-in-oil adjuvant delivery system. These findings were presented on May 23, 2007 by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology at CEL-SCI at the American Society of Microbiologists 107th annual general meeting in Toronto, Canada.
This new finding with CEL-1000 may have broad application for the enhancement of immune responses by individuals who have a poor immune response to vaccinations. It also has application for antigen sparing (reducing the amount/dose of antigen required for protective immunity), and to biodefense and pandemic settings for anti-infectious vaccines.
CEL-1000 has previously been shown to increase the antigenicity of hepatitis B virus (HBV). In challenge studies, CEL-1000 has also previously been shown to protect animals against infection against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria.
CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a broad-spectrum protection against infection in animal models. The innate immune system is generally accepted to be the first line of defense against infectious agents.
CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response. More information on CEL-1000 is available at http://www.cel-sci.com.
MAS-1 is a water-in-oil adjuvant delivery system owned by Mercia Pharma.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company's lead product Multikine(R) is cleared to enter a global Phase III clinical trial for a first line indication in advanced primary head and neck cancer in the U.S. and Canada.
CEL-SCI Corporation
http://www.cel-sci.com
VIENNA, Va., May 23 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (AMEX:CVM) announces that CEL-1000 increased the immune response against H5 avian influenza antigen in combination with MAS-1, a water-in-oil adjuvant delivery system. These findings were presented on May 23, 2007 by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology at CEL-SCI at the American Society of Microbiologists 107th annual general meeting in Toronto, Canada.
This new finding with CEL-1000 may have broad application for the enhancement of immune responses by individuals who have a poor immune response to vaccinations. It also has application for antigen sparing (reducing the amount/dose of antigen required for protective immunity), and to biodefense and pandemic settings for anti-infectious vaccines.
CEL-1000 has previously been shown to increase the antigenicity of hepatitis B virus (HBV). In challenge studies, CEL-1000 has also previously been shown to protect animals against infection against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria.
CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a broad-spectrum protection against infection in animal models. The innate immune system is generally accepted to be the first line of defense against infectious agents.
CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response. More information on CEL-1000 is available at http://www.cel-sci.com/.
MAS-1 is a water-in-oil adjuvant delivery system owned by Mercia Pharma.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company's lead product Multikine(R) is cleared to enter a global Phase III clinical trial for a first line indication in advanced primary head and neck cancer in the U.S. and Canada.
DATASOURCE: CEL-SCI Corporation
CONTACT: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460
Web site: http://www.cel-sci.com/
Could this technology be used by NNVC?
MFIC Corporation Unveils Breakthrough Microfluidics Reaction Technology for Drug Formulation
8:00a ET May 23, 2007 (Business Wire)
"The advent of MRT could potentially unlock uncounted drugs, vaccines and drug delivery systems that to date could not be formulated. It provides a critical advancement in the field of drug formulation and positions MFIC as a clear technology leader," said Bob Bruno, President & COO. "We anticipate introducing a line of equipment to facilitate the MRT process in the fourth quarter of this year, providing our customers with an additional effective and efficient solution for the creation of promising, new therapeutics."
MRT advances the manufacturing of nanosuspensions "bottom up" by chemical reactions or physical processes such as crystallization. It has been demonstrated for a variety of drugs using solvent and anti-solvent crystallization. This approach allows for a greater ability to control the growth rates of nanoparticles to produce uniform, optimally-sized nanoparticles in a more efficient, cost-effective manner. Conventional "top down" processes reduce particle sizes to the nano-level through a process of wet-milling, homogenization, micronization, and other techniques. MRT works by pumping liquid reactants through a coaxial feed system within a Microfluidizer(R) reaction chamber, which is based on impinging jet principals. The system provides precise control of the feed rate and mixing location.
"Through the use of MRT, MFIC engineers were able to produce nanosuspensions for several drugs, including two antibiotics, an antihistamine, an anticonvulsant and a non-steroidal anti-inflammatory," said Dr. Thomai Panagiotou, Vice President of Research and Development and the lead investigator and presenter of the study. "Importantly, MRT was demonstrated to be more effective in producing nanosuspensions than standard, particle size reducing methods," concluded Dr. Panagiotou.
The MRT technology and applications are outlined in the poster presented at the NSTI meeting. The poster will be accessible later this week on the Company's Web site at www.microfluidicscorp.com/.
About MFIC Corporation:
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid structures available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Forward Looking Statement:
Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer(R) materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.
SOURCE: MFIC Corporation
MFIC Corporation Robert P. Bruno, President & COO or Jack M. Swig, Investor Relations 617-969-5452 Fax: 617-965-1213 info@mfics.com www.mficcorp.com
MFIC Corporation Unveils Breakthrough Microfluidics Reaction Technology for Drug Formulation
8:00a ET May 23, 2007 (Business Wire)
"The advent of MRT could potentially unlock uncounted drugs, vaccines and drug delivery systems that to date could not be formulated. It provides a critical advancement in the field of drug formulation and positions MFIC as a clear technology leader," said Bob Bruno, President & COO. "We anticipate introducing a line of equipment to facilitate the MRT process in the fourth quarter of this year, providing our customers with an additional effective and efficient solution for the creation of promising, new therapeutics."
MRT advances the manufacturing of nanosuspensions "bottom up" by chemical reactions or physical processes such as crystallization. It has been demonstrated for a variety of drugs using solvent and anti-solvent crystallization. This approach allows for a greater ability to control the growth rates of nanoparticles to produce uniform, optimally-sized nanoparticles in a more efficient, cost-effective manner. Conventional "top down" processes reduce particle sizes to the nano-level through a process of wet-milling, homogenization, micronization, and other techniques. MRT works by pumping liquid reactants through a coaxial feed system within a Microfluidizer(R) reaction chamber, which is based on impinging jet principals. The system provides precise control of the feed rate and mixing location.
"Through the use of MRT, MFIC engineers were able to produce nanosuspensions for several drugs, including two antibiotics, an antihistamine, an anticonvulsant and a non-steroidal anti-inflammatory," said Dr. Thomai Panagiotou, Vice President of Research and Development and the lead investigator and presenter of the study. "Importantly, MRT was demonstrated to be more effective in producing nanosuspensions than standard, particle size reducing methods," concluded Dr. Panagiotou.
The MRT technology and applications are outlined in the poster presented at the NSTI meeting. The poster will be accessible later this week on the Company's Web site at www.microfluidicscorp.com/.
About MFIC Corporation:
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid structures available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Forward Looking Statement:
Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer(R) materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.
SOURCE: MFIC Corporation
MFIC Corporation Robert P. Bruno, President & COO or Jack M. Swig, Investor Relations 617-969-5452 Fax: 617-965-1213 info@mfics.com www.mficcorp.com
MFIC Corporation Unveils Breakthrough Microfluidics Reaction Technology for Drug Formulation
8:00a ET May 23, 2007 (Business Wire)
"The advent of MRT could potentially unlock uncounted drugs, vaccines and drug delivery systems that to date could not be formulated. It provides a critical advancement in the field of drug formulation and positions MFIC as a clear technology leader," said Bob Bruno, President & COO. "We anticipate introducing a line of equipment to facilitate the MRT process in the fourth quarter of this year, providing our customers with an additional effective and efficient solution for the creation of promising, new therapeutics."
MRT advances the manufacturing of nanosuspensions "bottom up" by chemical reactions or physical processes such as crystallization. It has been demonstrated for a variety of drugs using solvent and anti-solvent crystallization. This approach allows for a greater ability to control the growth rates of nanoparticles to produce uniform, optimally-sized nanoparticles in a more efficient, cost-effective manner. Conventional "top down" processes reduce particle sizes to the nano-level through a process of wet-milling, homogenization, micronization, and other techniques. MRT works by pumping liquid reactants through a coaxial feed system within a Microfluidizer(R) reaction chamber, which is based on impinging jet principals. The system provides precise control of the feed rate and mixing location.
"Through the use of MRT, MFIC engineers were able to produce nanosuspensions for several drugs, including two antibiotics, an antihistamine, an anticonvulsant and a non-steroidal anti-inflammatory," said Dr. Thomai Panagiotou, Vice President of Research and Development and the lead investigator and presenter of the study. "Importantly, MRT was demonstrated to be more effective in producing nanosuspensions than standard, particle size reducing methods," concluded Dr. Panagiotou.
The MRT technology and applications are outlined in the poster presented at the NSTI meeting. The poster will be accessible later this week on the Company's Web site at www.microfluidicscorp.com/.
About MFIC Corporation:
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid structures available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Forward Looking Statement:
Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer(R) materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.
SOURCE: MFIC Corporation
MFIC Corporation Robert P. Bruno, President & COO or Jack M. Swig, Investor Relations 617-969-5452 Fax: 617-965-1213 info@mfics.com www.mficcorp.com
Warning-7 emails from 7 different addresses on this German spam/scam penny stock!!!!
http://www.investorshub.com/boards/board.asp?board_id=7707
A record! SEVEN emails from these German spam/scammers from SEVEN , yes thats 7, DIFFERENT email addresses:
GERMAN MARKETS ARE TAKING OVER! T3R.F IS A HIDDEN GEM! WATCH IT ON
THURSDAY MAY 24!
Company: SKYFLYER
Symbol: T3R.F
Price: 0.33
Target: 0.98
WKN : A0LCMC
ISIN : US83082R1077
Market: Frankfurt
FRANKFURT IS WHERE THE NEXT BIG GAINS ARE! WATCH THE GROWTH WITH YOUR
OWN EYES! ADD T3R.F TO YOUR RADAR NOW!
The President of the North West Oil Group Mr. Ernest Malyshev Will Answer Questions on May 24, 2007 and on May 25, 2007 Be Released Audited Consolidated Financial Statement
MOSCOW -- (MARKET WIRE) -- May 23, 2007 -- The president of the North West Oil Group Inc. (PINKSHEETS: NWOG) Mr. Ernest Malyshev will receive telephone calls from investors on May 24, 2007 from 19.00 till 20.00 Moscow time. Phone number for connection is +7 (495) 621 11 15. We kindly ask the investors to formulate their questions particularly and briefly.
On May 25, 2007 will be released the audited consolidated financial statement preparing by LLC 'Audit-Invest-Consult'-based accounting firm of Moscow.
About North West Oil Group (formerly Nord Oil International): North West Oil Group is a non-reporting, publicly traded Oil & Gas company trading under the ticker symbol NWOG on the U.S. Pinksheets market.
Highlighted Links
North West Oil Group
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
--------------------------------------------------------------------------------
Contact:
Evgeniya Popova
North West Oil Group
Tel: +7 495 621 11 15
E-Mail: jane@szng.ru
Web: http://www.szng.ru
SOURCE: North-West Oil Group
The President of the North West Oil Group Mr. Ernest Malyshev Will Answer Questions on May 24, 2007 and on May 25, 2007 Be Released Audited Consolidated Financial Statement
MOSCOW -- (MARKET WIRE) -- May 23, 2007 -- The president of the North West Oil Group Inc. (PINKSHEETS: NWOG) Mr. Ernest Malyshev will receive telephone calls from investors on May 24, 2007 from 19.00 till 20.00 Moscow time. Phone number for connection is +7 (495) 621 11 15. We kindly ask the investors to formulate their questions particularly and briefly.
On May 25, 2007 will be released the audited consolidated financial statement preparing by LLC 'Audit-Invest-Consult'-based accounting firm of Moscow.
About North West Oil Group (formerly Nord Oil International): North West Oil Group is a non-reporting, publicly traded Oil & Gas company trading under the ticker symbol NWOG on the U.S. Pinksheets market.
Highlighted Links
North West Oil Group
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
--------------------------------------------------------------------------------
Contact:
Evgeniya Popova
North West Oil Group
Tel: +7 495 621 11 15
E-Mail: jane@szng.ru
Web: http://www.szng.ru
SOURCE: North-West Oil Group
>Through a part of the field runs the main regional road.<
Someone failed to proofread again,lol.
Newbies: check out spam/scammers before buying pinkies!
http://www.investorshub.com/boards/board.asp?board_id=7707
From Investrade:
Recently, an increase in fraudulent activity in brokerage accounts, involving OTC Bulletin Board and Pink Sheet stocks, across the U.S. and Canada has been reported by both the U.S. SEC and the Canadian IDA. Identity theft schemes involve the “hijacking” of accounts through “phishing” and “malware”. “Phishing” refers to emails that prompt a user to visit a Web-site (designed as an official web page) and enter personal information under a legitimate pretext. “Malware” or “spyware” involves malicious programs loaded on a user’s machine allowing intruder access or the logging of user activity for illegitimate use. It is important that customers always take strong precautions to protect their account information and computers.
For your protection all OTCBB and Pink Sheet stock orders must be called in to a broker.
1987! You just reminded me, I bought ADVR for .12 that year-I still have all my shares now worth about 4 cents but not to worry the "miricle" drug (at that time) is still waiting for a miracle :)
I also bought CVM that year and have traded it 3-4 times for some good profits. I sold last of it a couple of months ago for .76 and it has been trading in .90's this week. I have been waiting for it to go below .70 to jump back in :(
Lesson learned from biotech investing-you never know until FDA gives ok-then you never know after that. I know because I worked in pharma (recall)field for 40 years-thats why I know :)
I know one thing about NNVC-I am going to hold.
TVEN
Red Hot Opportunity!
Terrace Ventures Inc.
Sym: TVEN
Currrent Price: 0.235
Projjected Price: 0.80
TVEN is a tightly held company in a Booming sector! The company is
set to make a Major Announcement any day. Big merger? We are not
allowed to say, but we advise our readers to get in early!
The news hitting the street combines with the massive promotion are
going to blow this one off the charts!
CEL-SCI Presents Long-Term Cancer Survival Data With Multikine(R)
Monday May 21, 9:30 am ET
Multikine Improves Overall Survival by 33% 3.5 Years Post Surgery
VIENNA, Va., May 21 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM - News) announced today that its cancer drug Multikine® was shown to significantly increase long term overall survival in a Phase II study of head and neck cancer patients. The data were presented on May 20, 2007 at the First International Congress of the International Association of Oral Oncology in Amsterdam, the Netherlands, by Dr. Eyal Talor, Senior VP of Research and Manufacturing at CEL-SCI Corporation.
ADVERTISEMENT
Dr. Talor's presentation focused on the results obtained in CEL-SCI's final Phase II clinical trial of Multikine that was conducted in patients with head and neck cancer (oral squamous cell carcinoma -- OSCC). This final Phase II clinical trial was designed to assess thoroughly the positive safety and efficacy observations made in patients treated with Multikine in CEL-SCI's early Phase II trials. In the trial Multikine was given prior to standard care to recently diagnosed and not yet treated cancer patients.
The addition of Multikine to the first treatment (standard of care) of these patients resulted in a 33% improvement in the median overall survival at 3-1/2 years post-surgery, when compared to the survival results reported in 55 OSCC clinical trials published in the scientific literature between 1987 and 2007.
Multikine first-line treatment also resulted in an improvement of the 2- year local regional over the published local regional control rate. It is clinically recognized that recurrence of disease in head and neck cancer is associated with a very poor prognosis. Multikine treatment did not result in any severe adverse events (SAE) in this Phase II clinical trial and no SAEs related to Multikine have been reported in other trials conducted with Multikine either.
CEL-SCI received clearance from the United States Food and Drug Administration (FDA) to proceed to a Phase III clinical trial with Multikine earlier this year. The same treatment regimen that was used in CEL-SCI's final Phase II trial will be used in the upcoming Phase III trial that CEL-SCI will undertake since the results obtained in the final Phase II trial are thought to be indicative of the results one might expect in any Phase III trial of Multikine. The Phase III trial is designed to demonstrate a 10% increase in overall survival of patients treated with adjuvant Multikine therapy versus those treated only with the current standard of care.
Dr. Talor said, "Having shown a 33% increase in overall survival with no safety concerns in the final Phase II study, we are very hopeful that we will successfully reach the 10% increase in overall survival that is the primary endpoint of our Phase III trial. To further enhance the probability of meeting our primary endpoint, we are over-enrolling the study."
Documented data were available for 19 of the 22 patients in the follow-up portion of this clinical trial. Of the three patients who could not be evaluated in the follow-up study, one patient was known to be alive, but failed to give informed consent, and the other two were lost to follow-up. One patient died the day after definitive surgery, unrelated to Multikine therapy.
Head & neck cancer is an aggressive cancer that affects over 500,000 - 600,000 people per annum worldwide.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has received the go-ahead from the U.S. FDA and the Canadian Regulators to conduct a Phase III clinical trial in advanced primary head and neck cancer patients with its lead product Multikine. CEL-SCI's other products, which are currently in pre-clinical stage and have been funded with U.S. government support, have shown protection against a number of diseases in animal tests and are currently being tested against diseases associated with bio-defense and avian flu. The Company has operations in Vienna, Virginia and Baltimore, Maryland.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2006. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
--------------------------------------------------------------------------------
Source: CEL-SCI Corporation
BoonMarket.com: BoonMarket.com Announces Coverage of Unigene Laboratories, Inc.
SANTA BARBARA, CA, May 14, 2007 (M2 PRESSWIRE via COMTEX) -- BoonMarket.com announced today their renewed interest in Unigene Laboratories, Inc. (OTCBB: UGNE). UGNE has been mentioned on BoonMarket.com in the past and recent developments within the company have compelled BoonMarket.com to closely follow the company once again.
Don't be crazy enough to ignore the riveting insight we provide. In-depth analysis of this and other companies can be viewed through BoonMarket.com's special email alerts. You can sign up for these alerts for free (limited time only) by visiting http://visitor.constantcontact.com/email.jsp?m=1101186369563.
----------------------------------------------------
UGNE is currently up 3.31% on 360,468 shares traded. UGNE news from 5/11/07:
Unigene Announces Strong Increase in Revenue and Improved Quarterly Income for First Quarter 2007
Unigene Laboratories, Inc. reports its financial results for the quarter ended March 31, 2007.
Revenue for the three months ended March 31, 2007 increased to $6,328,000 compared to $387,000 for the three months ended March 31, 2006. Revenue from Fortical sales and royalties were $4,461,000 for the three months ended March 31, 2007.
Fortical royalties for the three months ended March 31, 2007 increased to $1,845,000 from $198,000 for the three months ended March 31, 2006. First quarter 2007 Fortical royalties include Upsher-Smith sales for the four month period of December 2006 through March 2007.
Fortical sales were $2,616,000 for the three months ended March 31, 2007. Sales to Novartis under our supply agreement were $1,408,000 for the three months ended March 31, 2007. There were no product sales for the three months ended March 31, 2006.
Operating income for the three months ended March 31, 2007 increased to $124,000 from an operating loss of $2,856,000 for the three months ended March 31, 2006.
Unigene's net loss for the three months ended March 31, 2007 was $244,000, or $.00 per share, compared to a net loss of $3,243,000, or $.04 per share for the three months ended March 31, 2006.
BoonMarket.com: BoonMarket.com Announces Coverage of Unigene Laboratories, Inc.
SANTA BARBARA, CA, May 14, 2007 (M2 PRESSWIRE via COMTEX) -- BoonMarket.com announced today their renewed interest in Unigene Laboratories, Inc. (OTCBB: UGNE). UGNE has been mentioned on BoonMarket.com in the past and recent developments within the company have compelled BoonMarket.com to closely follow the company once again.
Don't be crazy enough to ignore the riveting insight we provide. In-depth analysis of this and other companies can be viewed through BoonMarket.com's special email alerts. You can sign up for these alerts for free (limited time only) by visiting http://visitor.constantcontact.com/email.jsp?m=1101186369563.
----------------------------------------------------
UGNE is currently up 3.31% on 360,468 shares traded. UGNE news from 5/11/07:
Unigene Announces Strong Increase in Revenue and Improved Quarterly Income for First Quarter 2007
Unigene Laboratories, Inc. reports its financial results for the quarter ended March 31, 2007.
Revenue for the three months ended March 31, 2007 increased to $6,328,000 compared to $387,000 for the three months ended March 31, 2006. Revenue from Fortical sales and royalties were $4,461,000 for the three months ended March 31, 2007.
Fortical royalties for the three months ended March 31, 2007 increased to $1,845,000 from $198,000 for the three months ended March 31, 2006. First quarter 2007 Fortical royalties include Upsher-Smith sales for the four month period of December 2006 through March 2007.
Fortical sales were $2,616,000 for the three months ended March 31, 2007. Sales to Novartis under our supply agreement were $1,408,000 for the three months ended March 31, 2007. There were no product sales for the three months ended March 31, 2006.
Operating income for the three months ended March 31, 2007 increased to $124,000 from an operating loss of $2,856,000 for the three months ended March 31, 2006.
Unigene's net loss for the three months ended March 31, 2007 was $244,000, or $.00 per share, compared to a net loss of $3,243,000, or $.04 per share for the three months ended March 31, 2006.
GSPI
GPSI Announces Market Attack Into $1 Trillion Market!
Global Payment Solutions
Symbol: GPSI
Price: $0.03
GPSI announced its plans to address the huge influx of immigrant
workers
into the US that need banking solutions that they otherwise would not
qualify for. This market is expected to represent over $1 Trillion
dollars to be managed by 2008. GPSI provides viable solutions to this
market. This is hot, read the news and watch for more Monday! Get on
GPSI first thing Monday!
T2Y.F-new one from Frankfurt.
I cannot C & P some of these emails for some reason (ones with graphics). Any suggestions?
"three jeers for those that post deceitfully"
We shall know "who" in the final ending and will be dutifully reported .
Are'nt all crooks morons,lol?
More crooks caught on Wall Street:
http://articles.moneycentral.msn.com/Investing/CompanyFocus/ANewWaveOfInsiderTrading.aspx?page=all
Seems like for every crook caught on Wall Street 2 more pop up:
A new wave of insider trading
Some high-profile professionals -- lawyers, investment bankers and traders -- have admitted or are accused of scheming to grab illegal profits. A spike in takeover bids is driving the trend.
By Michael Brush
If crime doesn't pay, then it shouldn't come as a big surprise that criminal stupidity has its limits as a moneymaking enterprise.
Yet Wall Street appears to be awash in it.
In the past three months, the Securities and Exchange Commission has filed more than half a dozen cases that charge professionals at top brokerage houses, hedge funds and even some top accounting firms with insider-trading plots. The schemes could have earned more than $35 million.
Any gains weren't ill-gotten for long, though, mostly because of some outlandishly dumb moves. Among the allegations:
A vice president at Morgan Stanley used her mother's brokerage account to buy companies targeted for acquisition before the deals were announced.
A Hong Kong couple increased the size of their brokerage account 25-fold -- and made two wire transfers totaling $6.9 million -- just before making a massive illegal trade.
An investment banker made calls to Pakistan from his office phone to place trades driven by inside information.
"You have to be a moron to make a call from your office phone," says James Angel, a professor of finance at Georgetown University's McDonough School of Business in Washington, D.C. "It seems like there is an awful lot of stupidity going around, maybe because greed went to their heads."
Many of these folks are anything but amateurs. They include senior managers, hedge-fund partners, investment bankers, lawyers and traders from prestigious brokerage firms such as UBS AG (UBS, news, msgs), Credit Suisse (CS, news, msgs), Morgan Stanley (MS, news, msgs) and Bear Stearns (BSC, news, msgs). Some are lawyers from top law firms in New York and Los Angeles, or accountants who worked at PricewaterhouseCoopers and Ernst & Young.
What's driving the trend is a huge spike in takeover deals, such as Alcoa's (AA, news, msgs) recent bid for Canada's Alcan (AL, news, msgs) and News Corp.'s (NWS, news, msgs) bid for Dow Jones (DJ, news, msgs).
"Unfortunately, one of the things that naturally follows when there are big deals in the making is that you get a lot of pilot fish out there squirming around," says Michael Malloy, a former SEC enforcement attorney who teaches at the University of the Pacific's McGeorge School of Law in Sacramento, Calif.
Here's a taste of the brazen behavior in the recent insider-trading schemes -- all culled from the SEC cases filed in the past three months. Several of the accused have pleaded guilty to criminal charges, and a few have pleaded not guilty.
A debt-elimination plan gone bad?
In 2001, an employee of UBS Securities was said to be wondering how he would settle a $25,000 personal loan from a friend. Then, the SEC says, he came up with a bright idea: Why not pay it off in stock tips? After all, as a manager in the equity-research department at UBS, he knew about upcoming changes in stock recommendations by UBS analysts before they became public. So, according to the SEC, he hatched the plan with his creditor-friend, and they agreed to split after-tax profits.
The arrangement went on for years, the SEC says, as the two exchanged coded text messages on disposable cell phones to swap stock tips and set up meeting places to share the winnings. Before the scheme unraveled last year, according to the SEC, it had brought in more than $5 million on trades placed ahead of UBS ratings changes on several widely traded stocks, including Whole Foods Market (WFMI, news, msgs) and Amgen (AMGN, news, msgs).
Video on MSN Money
No ordinary rally
If this were a typical rally, technology and financial stocks would be leading the market right now. But instead, cyclicals -- like basic materials stocks and consumer companies -- are out in front. That's not a good sign, says MSN Money's Jim Jubak.
The trades were carried out in private accounts, two hedge funds and an account in the name of the father-in-law of one of the men. The UBS manager has pleaded not guilty, but the friend who lent him money has pleaded guilty. An assistant who placed many of the trades -- an employee of Bear Stearns at the time -- caught on and placed piggyback trades in his own account. He was busted, too, and has pleaded guilty.
A fox, a henhouse and a bust
A Morgan Stanley compliance lawyer in charge of preventing leaks was allegedly profiting from them.
During 2004 and 2005, the attorney gave undisclosed takeover news to her husband, who passed it along to a broker in Florida, and they shared the profits from illicit trades made using these tips. The compliance officer, her husband and the broker have pleaded guilty to securities fraud.
All in the family
In a family-run operation, a father and three sons set up a hedge fund to trade on illegal inside information, perhaps hoping the fund would cover their tracks. The sons and a friend linked to the plot had worked at prominent law firms and the accounting firms PricewaterhouseCoopers and Ernst & Young.
They obtained insider information from their father, who had a senior management position at Taro Pharmaceutical Industries (TAROF, news, msgs). The SEC says he provided advance knowledge of earnings news and of Food and Drug Administration approval of new drugs. The scheme netted the group $3.7 million. The father, his sons and a friend who helped with the plot have pleaded guilty to securities fraud.
Continued: Our man in Pakistan
Our man in Pakistan
For the past year, says the SEC, an investment banker working on mergers and acquisitions for Credit Suisse in New York regularly called a banker in Pakistan to tell him about pending takeover deals so they both could profit on the news.
In the most recent case, he allegedly called the Pakistani banker at least five times from his office phone in February to tip him off about the takeover of TXU Corp. (TXU, news, msgs), announced Feb. 26. The Pakistani made nearly $5 million on TXU options when the deal was announced, the SEC says. He also profited from tips on eight other takeover deals involving U.S. companies, including Jacuzzi Brands and Caremark Rx, a prescription-drug distributor bought by CVS Caremark (CVS, news, msgs).
In many cases, the SEC alleges, the Pakistani banker placed his trades just minutes after getting tips on the phone from New York. The Credit Suisse banker allegedly made money by opening a brokerage account in Pakistan.
Marc Mukasey, an attorney with Bracewell & Giuliani who represents the Credit Suisse banker, says the SEC does not have enough evidence to support its allegations. "We are going to fight the government’s case vigorously," he said.
Call Mom -- she'll help
Over the past two years, a Morgan Stanley vice president in New York reportedly used online brokerage accounts in the name of her mother, who lives in Beijing, to buy stocks ahead of takeover news. The employee knew of the pending deals through her job, according to the SEC, which thinks she and her husband made more than $600,000 in the scheme.
The two may have thought they were covering their tracks by using accounts of a Chinese resident. But the SEC says that on the days the trades were made, the accounts were accessed through Internet connections from the banker's home in New Jersey or from her husband's employer at the time, ING Investment Management Services.
Neither the husband and wife nor their attorney could be reached for comment.
Conservative no more
In the two weeks leading up to the May 1 announcement by News Corp. that it wanted to buy Dow Jones, a Hong Kong couple accumulated 415,000 shares of Dow Jones. Kan King Wong and his wife, Charlotte Ka On Wong Leung, would have made $8.2 million on the deal.
That's four times the net worth they reported to Merrill Lynch in 2004 when they opened the brokerage account used for the trades.
Dow Jones stock jumped 58% on the day news of the proposed deal broke, rising above $57 a share. The SEC says the couple left an obvious trail: two wire transfers worth $6.9 million into their brokerage account, including one from Brussels, Belgium. Their Dow Jones purchases also stick out because they increased the size of their brokerage account by 25 times. And before their Dow Jones purchases, the couple had most of their money in the account in bonds. The SEC has frozen their account, and the couple have a court date June 18 in New York.
Not-so-isolated cases
So what about the folks who aren't as brazen in their wrongdoing? There's some indication that, even as the SEC makes headlines with high-profile busts, there are plenty of folks making money on insider trading:
On May 8, someone bought 4,000 call options, giving them the right to purchase shares of CBOT Holdings (BOT, news, msgs) at $200 through the third week in June, points out Jon Najarian of optionMONSTER, which tracks unusual options activity closely to hunt for trading ideas. An hour later, CNBC reported that CBOT Holdings was planning to meet with a suitor to discuss its bid buy CBOT Holdings. That immediately drove CBOT shares higher. Indeed, a potential buyer increased its bid later that week. Najarian estimates the buyers of the options made a paper profit of over $2 million in a few days.
Buyers snatched up 29,000 call options in Alcoa on May 4, notes Joe Hargett of Schaeffer's Investment Research. That was the last trading day before Alcoa announced plans to buy Alcan. Speculators also bought big call positions in Alcan ahead of the news, Najarian says. After the news broke, both stocks rose, driving up the value of options -- which can increase dramatically more than the underlying stock. The Alcoa options increased fourfold. But the buyers of Alcan options did even better. Najarian estimates that Alcan call options purchased just before the deal news for $17,000 turned into $2.9 million. He says buyers of another call position earned more than $3 million on an investment of $146,000.
There was also heavy buying in Dow Jones call options on April 25 and April 30, the day before the News Corp. bid was disclosed. Najarian estimates those buyers made around $6 million. The SEC has not charged anyone with insider trading in the purchase of those options.
"Apparently, a significant number of Wall Street professionals have forgotten the lessons of the late 1980s, when insider trading scandals rocked Wall Street," says Peter Bresnan, the deputy director of the SEC's enforcement division. "If they need to learn that again, we will teach them
http://articles.moneycentral.msn.com/Investing/CompanyFocus/ANewWaveOfInsiderTrading.aspx?page=all